Author Archives: Joana Fernandes, PhD

Dragonfly Therapeutics and Celgene Partnering on Blood-Cancer Therapies

Dragonfly Therapeutics and Celgene have teamed up to develop therapies for multiple myeloma and other blood cancers. The partners will use Dragonfly’s TriNKET immunotherapy platform, which is based on Natural Killer (NK) cells. Under the agreement, Dragonfly will receive $33 million up-front to develop blood-cancer treatments, while Celgene will obtain…

Combo Therapy After Stem Cell Transplant Improves Survival in Myeloma Patients, Trial Finds

Combination treatment with Velcade (bortezomib) and Thalomid (thalidomide) may significantly improve survival of multiple myeloma patients who received a stem cell transplant, according to recent results of a Phase 3 trial. The study, “Bortezomib And Thalidomide Maintenance After Stem-Cell Transplantation For Multiple Myeloma: A PETHEMA/GEM trial,” was published in…

Multiple Myeloma Studied in New Mouse Model Developed at Yale

Understanding how multiple myeloma develops and responds to therapies may be easier using a new mouse model developed at Yale University School of Medicine. The model supports the growth of cells derived from patients with multiple myeloma or the disease’s precursor states. The study, “Microenvironment-Dependent Growth Of Preneoplastic And Malignant Plasma…

PharmaMar Seeks EU Approval for Aplidin to Treat Multiple Myeloma

PharmaMar has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for the use of Aplidin (plitidepsin) in combination with Decadron (dexamethasone, an anti-inflammatory drug) for the treatment of relapsed/refractory multiple myeloma patients. The EMA’s decision is expected by the second half of 2017. The application was supported by…